226 related articles for article (PubMed ID: 11668217)
21. Development of a PCR-based strategy for CYP2D6 genotyping including gene multiplication of worldwide potential use.
Dorado P; Cáceres M; Pozo-Guisado E; Wong ML; Licinio J; Llerena A
Biotechniques; 2005 Oct; 39(10 Suppl):S571-4. PubMed ID: 18957039
[TBL] [Abstract][Full Text] [Related]
22. Pharmacokinetics of codeine and its metabolite morphine in ultra-rapid metabolizers due to CYP2D6 duplication.
Kirchheiner J; Schmidt H; Tzvetkov M; Keulen JT; Lötsch J; Roots I; Brockmöller J
Pharmacogenomics J; 2007 Aug; 7(4):257-65. PubMed ID: 16819548
[TBL] [Abstract][Full Text] [Related]
23. [Assessment of CYP2D6 activity as a form of optimizing antidepressant therapy].
Szewczuk-Bogusławska M; Grzesiak M; Beszłej JA; Kiejna A
Psychiatr Pol; 2004; 38(6):1093-104. PubMed ID: 15779673
[TBL] [Abstract][Full Text] [Related]
24. Comparison of two CYP2D6 genotyping methods and assessment of genotype-phenotype relationships.
Chou WH; Yan FX; Robbins-Weilert DK; Ryder TB; Liu WW; Perbost C; Fairchild M; de Leon J; Koch WH; Wedlund PJ
Clin Chem; 2003 Apr; 49(4):542-51. PubMed ID: 12651805
[TBL] [Abstract][Full Text] [Related]
25. Analysis of the CYP2D6 gene mutations and their consequences for enzyme function in a West African population.
Griese EU; Asante-Poku S; Ofori-Adjei D; Mikus G; Eichelbaum M
Pharmacogenetics; 1999 Dec; 9(6):715-23. PubMed ID: 10634134
[TBL] [Abstract][Full Text] [Related]
26. The AmpliChip CYP450 genotyping test: Integrating a new clinical tool.
de Leon J; Susce MT; Murray-Carmichael E
Mol Diagn Ther; 2006; 10(3):135-51. PubMed ID: 16771600
[TBL] [Abstract][Full Text] [Related]
27. CYP2D6 basic genotyping as a potential tool to improve the antiemetic efficacy of ondansetron in prophylaxis of postoperative nausea and vomiting.
Niewiński PA; Wojciechowski R; Śliwiński M; Hurkacz ME; Głowacka K; Orzechowska-Juzwenko K; Wiela-Hojeńska AK
Adv Clin Exp Med; 2018 Nov; 27(11):1499-1503. PubMed ID: 30058787
[TBL] [Abstract][Full Text] [Related]
28. Polymorphic cytochrome P450 2D6: humanized mouse model and endogenous substrates.
Yu AM; Idle JR; Gonzalez FJ
Drug Metab Rev; 2004 May; 36(2):243-77. PubMed ID: 15237854
[TBL] [Abstract][Full Text] [Related]
29. Side effects associated with ultrarapid cytochrome P450 2D6 genotype among women with early stage breast cancer treated with tamoxifen.
Rolla R; Vidali M; Meola S; Pollarolo P; Fanello MR; Nicolotti C; Saggia C; Forti L; Agostino FD; Rossi V; Borra G; Stratica F; Alabiso O; Bellomo G
Clin Lab; 2012; 58(11-12):1211-8. PubMed ID: 23289191
[TBL] [Abstract][Full Text] [Related]
30. Development of a PCR-based strategy for CYP2D6 genotyping including gene multiplication of worldwide potential use.
Dorado P; Cáceres MC; Pozo-Guisado E; Wong ML; Licinio J; Llerena A
Biotechniques; 2005 Oct; 39(4):571-4. PubMed ID: 16235570
[TBL] [Abstract][Full Text] [Related]
31. In vivo assessment of the metabolic activity of CYP2D6 diplotypes and alleles.
Hertz DL; Snavely AC; McLeod HL; Walko CM; Ibrahim JG; Anderson S; Weck KE; Magrinat G; Olajide O; Moore S; Raab R; Carrizosa DR; Corso S; Schwartz G; Peppercorn JM; Evans JP; Jones DR; Desta Z; Flockhart DA; Carey LA; Irvin WJ
Br J Clin Pharmacol; 2015 Nov; 80(5):1122-30. PubMed ID: 25907378
[TBL] [Abstract][Full Text] [Related]
32. Coordinated intrahepatic and extrahepatic regulation of cytochrome p4502D6 in healthy subjects and in patients after liver transplantation.
Carcillo JA; Adedoyin A; Burckart GJ; Frye RF; Venkataramanan R; Knoll C; Thummel K; Roskos L; Wilson JW; Sereika S; Romkes M; Bebia Z; Branch RA
Clin Pharmacol Ther; 2003 May; 73(5):456-67. PubMed ID: 12732845
[TBL] [Abstract][Full Text] [Related]
33. Extension of a pilot study: impact from the cytochrome P450 2D6 polymorphism on outcome and costs associated with severe mental illness.
Chou WH; Yan FX; de Leon J; Barnhill J; Rogers T; Cronin M; Pho M; Xiao V; Ryder TB; Liu WW; Teiling C; Wedlund PJ
J Clin Psychopharmacol; 2000 Apr; 20(2):246-51. PubMed ID: 10770465
[TBL] [Abstract][Full Text] [Related]
34. Impact of the ultrarapid metabolizer genotype of cytochrome P450 2D6 on metoprolol pharmacokinetics and pharmacodynamics.
Kirchheiner J; Heesch C; Bauer S; Meisel C; Seringer A; Goldammer M; Tzvetkov M; Meineke I; Roots I; Brockmöller J
Clin Pharmacol Ther; 2004 Oct; 76(4):302-12. PubMed ID: 15470329
[TBL] [Abstract][Full Text] [Related]
35. The impact of cytochrome P450-2D6 genotype on the use and interpretation of therapeutic drug monitoring in long-stay patients treated with antidepressant and antipsychotic drugs in daily psychiatric practice.
Mulder H; Herder A; Wilmink FW; Tamminga WJ; Belitser SV; Egberts AC
Pharmacoepidemiol Drug Saf; 2006 Feb; 15(2):107-14. PubMed ID: 16294366
[TBL] [Abstract][Full Text] [Related]
36. Association between aripiprazole pharmacokinetics and CYP2D6 phenotypes: A systematic review and meta-analysis.
Zhang X; Xiang Q; Zhao X; Ma L; Cui Y
J Clin Pharm Ther; 2019 Apr; 44(2):163-173. PubMed ID: 30565279
[TBL] [Abstract][Full Text] [Related]
37. Association between cytochrome P450 2D6 genotype and harm avoidance.
Roberts RL; Luty SE; Mulder RT; Joyce PR; Kennedy MA
Am J Med Genet B Neuropsychiatr Genet; 2004 May; 127B(1):90-3. PubMed ID: 15108188
[TBL] [Abstract][Full Text] [Related]
38. Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6): clinical consequences, evolutionary aspects and functional diversity.
Ingelman-Sundberg M
Pharmacogenomics J; 2005; 5(1):6-13. PubMed ID: 15492763
[TBL] [Abstract][Full Text] [Related]
39. Challenges in CYP2D6 phenotype assignment from genotype data: a critical assessment and call for standardization.
Hicks JK; Swen JJ; Gaedigk A
Curr Drug Metab; 2014 Feb; 15(2):218-32. PubMed ID: 24524666
[TBL] [Abstract][Full Text] [Related]
40. Quantitation of human cytochrome P450 2D6 protein with immunoblot and mass spectrometry analysis.
Yu AM; Qu J; Felmlee MA; Cao J; Jiang XL
Drug Metab Dispos; 2009 Jan; 37(1):170-7. PubMed ID: 18832475
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
